

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4280509

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MATTHEW DOWLING	02/17/2017
RECEIVING PARTY DATA		
Name:	GEL-E, INC.	
Street Address:	387 TECHNOLOGY DR.	
Internal Address:	SUITE 3110B	
City:	COLLEGE PARK	
State/Country:	MARYLAND	
Postal Code:	20742	
PROPERTY NUMBERS Total: 3		
	Property Type	Number
	Application Number:	61779706
	Application Number:	14208820
	PCT Number:	US2014025896
CORRESPONDENCE DATA		
Fax Number:	(509)694-2042	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4433157929	
Email:	jmorales@moralesq.com	
Correspondent Name:	JOSEPH L. MORALES	
Address Line 1:	6628 WALNUTWOOD CIR	
Address Line 4:	BALTIMORE, MARYLAND 21212	
ATTORNEY DOCKET NUMBER:	1515.20500	
NAME OF SUBMITTER:	JOSEPH L. MORALES	
SIGNATURE:	/Joseph L. Morales/	
DATE SIGNED:	02/17/2017	
Total Attachments: 2		
source=11792#page1.tif		
source=11792#page2.tif		

ASSIGNMENT

WHEREAS, I, Matthew Dowling, a citizen of the United States, having a mailing address at 387 Technology Dr., Suite 3110B, College Park, MD 20742 (hereinafter referred to as ASSIGNOR), am the inventor or a joint inventor of the Inventions set forth in the following:

United States Provisional Patent Application entitled "Advanced Functional Biocompatible Polymer Putty Used as a Hemostatic Agent for Treating Damaged Tissue and Cells" filed on March 13, 2013, and assigned Serial No. 61/779,706.

United States Utility Patent Application entitled "Advanced Functional Biocompatible Polymer Putty Used as a Hemostatic Agent for Treating Damaged Tissue and Cells" filed on March 13, 2014, and assigned Serial No. 14/208,820, claiming priority from Provisional Application Number 61/779,706.

International Patent Application entitled "Advanced Functional Biocompatible Polymer Putty Used as a Hemostatic Agent for Treating Damaged Tissue and Cells" filed on March 13, 2014, and assigned Serial No. PCT/US2014/025896.

(the "Applications").

WHEREAS, Assignor assigned his rights to Remedium Technologies, Inc, pursuant to a certain Non-Disclosure and Assignment Agreement signed on July 6, 2007.

WHEREAS, Remedium Technologies, Inc. formally changed its name to GEL-E, Inc. on July 11, 2016.

WHEREAS, Gel-E, Inc., a Delaware corporation having a place of business at 387 Technology Dr., Suite 3110B, College Park, MD 20742 (hereinafter referred to as ASSIGNEE), is desirous of acquiring the entire right, title and interest in and to the Inventions, the Applications, and to any letters patent in regard to the Inventions listed above that may be granted therefor in all countries throughout the world.

I believe myself to be as sole or joint inventor of one or more of the inventions claimed in the above-referenced applications. The above-referenced applications were authorized to be made by me. I hereby acknowledge that any willful false statement made in this statement is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of the Federal Regulations §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) or equivalent and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the ASSIGNOR hereby sells, transfers, assigns, and sets over to the ASSIGNEE, and to its

Assignment

Application Serial Number: 14/208,820

Page 2 of 2

successors, assigns, and legal representatives, the entire right, title and interest in and to the Inventions and the Applications, for the entire world, including (without limitation) the United States and all foreign countries, and to all Letters Patent, non-provisional applications, divisions, continuations, continuations-in-part, substitutions, reissues, reexaminations, and extensions to be obtained therefor, and in and to all rights of priority resulting from the filing of the Applications, together with the right to sue and recover for, and the right to profits or damages due or accrued arising out of or in connection with, any and all past, present or future infringement of the Inventions. The ASSIGNOR agrees to cooperate with the ASSIGNEE in obtaining and sustaining any or all Letters Patent, but at the expense of the ASSIGNEE. The Commissioner of Patents is hereby authorized and requested to issue any and all Letters Patent solely, in accordance with this Assignment, to the ASSIGNEE, its successors, legal representatives and assigns as the ASSIGNEE of the entire rights, title and interest therein.

The ASSIGNOR further agrees to communicate to the ASSIGNEE or its representatives any facts known to the ASSIGNOR respecting the Inventions, and at the expense of the ASSIGNEE, to testify in any legal proceedings, sign all lawful papers, execute all division, continuation, continuation-in-part, substitution, reissue, reexamination, and extension applications, execute all necessary assignment papers to cause any and all of said Letters Patent to be issued to the ASSIGNEE, make all rightful oaths and generally to do everything necessary or desirable to aid the ASSIGNEE, its successors and assigns, to obtain and enforce proper protection for the Inventions in the United States and in any and all foreign countries.

IN WITNESS WHEREOF, the ASSIGNOR has executed this Assignment as an instrument under seal on the date written below.

02-17-2017
Date


Matthew Dowling

11790v1